Therapeutic application of thalidomide in multiple myeloma

被引：15

作者：

Kyle, RA ^{[1
]}

Rajkumar, SV ^{[1
]}

机构：

[1] Mayo Clin, Dept Internal Med, Div Hematol, Rochester, MN 55905 USA

来源：

SEMINARS IN ONCOLOGY | 2001年 / 28卷 / 06期

关键词：

D O I：

10.1053/sonc.2001.28612

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：583 / 587

页数：5

共 21 条

[1]

Cheng D, 1999, BLOOD, V94, p315A

[2]

Coleman M, 2000, BLOOD, V96, p167A

[3]

Durie BGM, 1999, BLOOD, V94, p316A

[4] Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma [J].

Juliusson, G ;

Celsing, F ;

Turesson, I ;

Lenhoff, S ;

Adriansson, M ;

Malm, C .

BRITISH JOURNAL OF HAEMATOLOGY, 2000, 109 (01) :89-96

[5]

Kneller A, 2000, BRIT J HAEMATOL, V108, P391

[6]

Neben K, 1999, BLOOD, V94, p124A

[7] Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma. [J].

Rajkumar, SV ;

Gertz, MA ;

Witzig, TE .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (13) :972-973

[8] Thalidomide in the treatment of relapsed multiple myeloma [J].

Rajkumar, SV ;

Fonseca, R ;

Dispenzieri, A ;

Lacy, MQ ;

Lust, JA ;

Witzig, TE ;

Kyle, RA ;

Gertz, MA ;

Greipp, PR .

MAYO CLINIC PROCEEDINGS, 2000, 75 (09) :897-901

[9]

Rajkumar SV, 2000, ONCOLOGY-NY, V14, P11

[10]

Rajkumar SV, 2000, BLOOD, V96, p364A

← 1 2 3 →